Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

TSE:7177
TSE:7177Capital Markets

GMO Financial Holdings FY 2025 Net Margin Surge Challenges Bearish Profitability Narratives

GMO Financial Holdings (TSE:7177) has wrapped up FY 2025 with fourth quarter revenue of ¥9,996 million and basic EPS of ¥13.04, while trailing twelve month EPS stands at ¥88.55. The company has seen quarterly revenue move from ¥9,223 million and EPS of ¥10.48 in Q4 FY 2024 to a range of ¥9,996 million to ¥13,201 million and EPS between ¥13.04 and ¥31.42 through FY 2025. This performance is supported by trailing twelve month revenue of ¥46,387 million and net income of ¥10,448 million. Margins...
TSX:FF
TSX:FFMetals and Mining

First Mining Gold (TSX:FF) Valuation Check After CAD 500 Million Shelf Registration Filing

First Mining Gold (TSX:FF) has filed a CAD 500 million omnibus shelf registration for common and preferred shares, warrants, and units. This filing gives the company broad flexibility around potential future financing or project related moves. See our latest analysis for First Mining Gold. The shelf filing lands after a sharp run in the shares, with a 90 day share price return of 109.52% and a very large 1 year total shareholder return. However, the 7 day share price return of 17.50% and 1...
NYSE:AESI
NYSE:AESIEnergy Services

Is Atlas Energy Solutions (AESI) Pricing Reflecting Its Recent Rebound And DCF Implied Upside Potential

If you are wondering whether Atlas Energy Solutions is attractively priced or not, it helps to step back and separate the recent headlines from what the numbers actually say about value. The share price closed at US$11.86, with returns of 1.5% over the last 7 days and 21.3% over the last 30 days, while the 1-year return sits at a 42.8% decline. Taken together, these figures suggest that recent sentiment has shifted compared with the longer-term experience. Recent coverage around Atlas Energy...
NYSE:GPN
NYSE:GPNDiversified Financial

Could Global Payments’ Upbeat Earnings Signals Reveal a Deeper Competitive Edge for GPN?

Recent analyst commentary has highlighted Global Payments as a growth-focused payments infrastructure provider, citing favorable growth metrics, above-industry EPS expectations, strong cash flow trends, and positive earnings estimate revisions ahead of its previously announced fourth-quarter and full-year 2025 results release scheduled for February 18, 2026. This mix of solid growth indicators and improving analyst expectations stands out in a competitive payments landscape where many rivals...
CPSE:CARL B
CPSE:CARL BBeverage

Does Carlsberg (CPSE:CARL B) Offer Value After Recent Share Price Strength

Wondering whether Carlsberg’s current share price really reflects what you are getting as an investor? This article walks through the numbers so you can judge the value for yourself. Carlsberg’s shares last closed at DKK 939.0, with returns of 10.2% over 7 days, 13.5% over 30 days, 13.7% year to date, 22.2% over 1 year, 5.9% over 3 years and 11.7% over 5 years. This provides useful context before thinking about what the stock might be worth. Recent coverage around Carlsberg has focused on...
CNSX:FLM
CNSX:FLMMetals and Mining

TSX Penny Stocks To Watch: 3 Picks With Market Caps Under CA$40M

The TSX has kicked off its fourth-quarter earnings season with a strong start, reflecting broad-based growth across multiple sectors. For investors looking beyond the major players, penny stocks—though an outdated term—still hold relevance as they can offer surprising value and potential for growth. In this article, we explore several penny stocks that combine solid fundamentals with the potential to stand out in today's market landscape.
NYSEAM:GROY
NYSEAM:GROYMetals and Mining

Is Gold Royalty (GROY) Offering Value After A 192% One Year Share Price Jump

If you are trying to figure out whether Gold Royalty is genuinely good value or just riding hype, starting with a clear view of its current valuation is essential. Gold Royalty's share price, last seen at US$4.35, has had mixed short term moves, with a 10.3% decline over the last 7 days, a 4.3% gain over 30 days, and returns of 6.6% year to date and 191.9% over the past year. Recent commentary around Gold Royalty has focused on its position within the gold royalty space and investor interest...
OM:VITR
OM:VITRBiotechs

Vitrolife (OM:VITR) Q4 Loss Of SEK 5.3b Tests Bullish Turnaround Narratives

Vitrolife FY 2025 earnings snapshot Vitrolife (OM:VITR) closed FY 2025 with fourth quarter revenue of SEK 892 million and a loss per share of SEK 39.23, as net income excluding extra items came in at a loss of SEK 5,313 million. Over the past year, the company has seen quarterly revenue range from SEK 835 million to SEK 892 million, while EPS moved from SEK 1.03 in Q4 2024 to SEK 0.74 in Q2 and Q1 2025, before swinging to a loss in Q4. For investors, the headline story is that solid top line...
OTCPK:BSEM
OTCPK:BSEMPharmaceuticals

Is It Time To Revisit BioStem Technologies (OTCPK:BSEM) After Its Recent Share Price Swings?

If you are trying to work out whether BioStem Technologies at around US$5.95 is attractively priced or not, you are in the right place. The share price has been volatile recently, with a 51.3% gain over the last 30 days, a 22.6% decline over the last week, a 52.3% gain year to date, and a 67.1% decline over the last year, alongside very large gains over 3 and 5 years. These sharp moves have come as investors react to ongoing developments around the company and its position in the...
NasdaqGS:FWRG
NasdaqGS:FWRGHospitality

A Look At First Watch Restaurant Group (FWRG) Valuation After Recent Share Price Gains

What the recent price move might mean for First Watch Restaurant Group (FWRG) First Watch Restaurant Group (FWRG) has drawn fresh attention after a recent share price move, with the stock closing at $17.24 and sitting on a month return of about 7% and year to date gain near 12%. See our latest analysis for First Watch Restaurant Group. Against that latest move, the 7 day share price return of 6.49% and 30 day share price return of 7.28% sit alongside a year to date share price return of...
NYSE:IQV
NYSE:IQVLife Sciences

Is Now The Moment To Reassess IQVIA (IQV) After Its Recent Share Price Slide

Wondering whether IQVIA Holdings is offering good value at its current share price, or if you are better off waiting on the sidelines? This breakdown will help you frame the numbers clearly. IQVIA's share price last closed at US$202.54, with a 15.5% decline over 7 days, a 13.7% decline over 30 days and a 10.1% decline year to date, while the 1 year return shows a 1.4% decline and the 3 year return shows a 14.0% decline, compared with a 5 year return of 6.6%. Recent price moves sit against a...
TSE:7267
TSE:7267Auto

Honda Motor (TSE:7267) Is Up 7.0% After December Output Rebounds And US Exports Surge

Honda Motor reported that its global vehicle production rose 4.3% in December 2025 to 283,161 units, partially reversing a prior month’s semiconductor-driven slump even as full-year output fell almost 9%. Exports from Japan grew by almost 20% for 2025, with shipments to the US nearly quadrupling while exports to Europe recorded an 11% decline, highlighting a sharp regional shift in demand. We will now examine how Honda’s December production rebound and sharply higher exports to the US...
ENXTPA:DEC
ENXTPA:DECMedia

JCDecaux Expands Global Programmatic DOOH Offer As Investors Weigh Valuation

JCDecaux has launched what it calls the world's first global programmatic Digital Out-of-Home media solution. The offer extends beyond airports to include streets, transport hubs, and retail environments across multiple countries. The new platform is designed to give advertisers programmatic tools for targeting, real time activation, and campaign measurement on a worldwide scale. JCDecaux (ENXTPA:DEC), trading at €16.55, is already a major player in outdoor advertising, and this move into...
NYSE:PRU
NYSE:PRUInsurance

Prudential Financial (PRU) Margin Expansion Strengthens Bullish Narratives Despite Modest Growth Forecasts

Prudential Financial FY 2025 earnings snapshot Prudential Financial (PRU) has wrapped up FY 2025 with Q4 revenue of US$14.2 billion and basic EPS of US$2.56, taking trailing twelve month revenue to US$55.7 billion and EPS to US$10.05 as the shares trade around US$102.17. The company has seen quarterly revenue move from US$13.5 billion in Q1 2025 to US$17.9 billion in Q3 2025 before landing at US$14.2 billion in Q4, while basic EPS has ranged from US$1.49 to US$4.03 across the year. This gives...
NasdaqGS:EA
NasdaqGS:EAEntertainment

EA (EA) Q3 Net Margin Compression Challenges Bullish Earnings Growth Narratives

Electronic Arts (EA) just posted Q3 2026 results with revenue of US$1.9b and basic EPS of US$0.35, alongside net income of US$88m, as part of a year that has seen trailing 12 month revenue of US$7.3b and EPS of US$2.70. Over the past few quarters, the company has seen revenue move between US$1.67b and US$2.03b while quarterly EPS ranged from US$0.35 to about US$1.12, giving investors plenty to think about in terms of how these headline figures are flowing through to profitability. With...
NasdaqGS:CTAS
NasdaqGS:CTASCommercial Services

Is It Too Late To Consider Cintas (CTAS) After Long Term Share Price Gains

If you are wondering whether Cintas is fairly priced or if the share price has already run ahead of its value, this article will walk you through what the current market is implying and how that compares with several valuation checks. Cintas shares recently closed at US$192.61, with returns of 1.8% over the last 7 days, 3.9% over 30 days, 4.2% year to date and a 3.7% decline over the past year, alongside longer term returns of 79.9% over 3 years and 131.1% over 5 years. Recent coverage has...
NasdaqGS:IONS
NasdaqGS:IONSBiotechs

Ionis Regulatory Wins Highlight Growing Rare Disease Revenue Potential

Ionis Pharmaceuticals (NasdaqGS:IONS) received European Commission approval for Dawnzera to help prevent hereditary angioedema attacks in eligible patients. The US FDA granted Breakthrough Therapy designation to zilganersen for Alexander disease, recognizing its potential for a serious rare condition with high unmet need. Partner GSK reported positive Phase 3 results for bepirovirsen, supporting potential regulatory filings for the hepatitis B candidate. Ionis Pharmaceuticals focuses on RNA...